Admitted for the management of an acute deep vein thrombosis, a -year-old female with systemic lupus erythematosus requires inpatient anticoagulation. She recently returned from a long international flight and developed sudden left calf swelling. Venous duplex ultrasonography confirms a new proximal thrombus. Her medical history is also notable for two spontaneous abortions and a prior diagnosis of antiphospholipid syndrome. She is prescribed an intravenous unfractionated heparin infusion. Before initiating the medication, baseline laboratory tests are obtained:
| Laboratory Test | Result | Reference Range |
|---|---|---|
| Hemoglobin | g/dL | - g/dL |
| Platelet count | - | |
| Creatinine | mg/dL | - mg/dL |
| Prothrombin time (PT) | seconds | - seconds |
| Activated partial thromboplastin time (aPTT) | seconds | - seconds |
Which of the following is the most appropriate laboratory test to monitor and titrate this patient's intravenous therapy?
- ASerial activated partial thromboplastin time (aPTT) measurements
- BProthrombin time and International Normalized Ratio (PT/INR)
- Anti-factor Xa levelCevap
- DThrombin time
- ESerial D-dimer measurements
Cevap
Anti-factor Xa level
The correct answer identifies the anti-factor Xa level as the best monitoring parameter. This patient has antiphospholipid syndrome (APS), which is strongly associated with the presence of lupus anticoagulant. Lupus anticoagulant binds to phospholipids in the laboratory assay, causing an artifactual prolongation of the baseline activated partial thromboplastin time (aPTT). Because standard unfractionated heparin protocols rely on tracking the prolongation of the aPTT, using this test in a patient whose aPTT is already prolonged at baseline would misleadingly suggest the heparin dose is therapeutic or supratherapeutic. This leads to profound under-dosing and clinical failure. The anti-factor Xa assay directly measures the ability of heparin-bound antithrombin to inhibit factor Xa and is unaffected by antiphospholipid antibodies.
Adım Adım Çözüm
Anahtar Kavram
In patients with antiphospholipid syndrome and a lupus anticoagulant, the baseline aPTT is often artifactually prolonged. Consequently, unfractionated heparin therapy cannot be reliably monitored with aPTT and must instead be titrated using an anti-factor Xa assay to prevent dangerous under-dosing.